106 research outputs found

    Right Handed Weak Currents in Sum Rules for Axialvector Constant Renormalization

    Get PDF
    The recent experimental results on deep inelastic polarized lepton scattering off proton, deuteron and 3^{3}He together with polari% zed neutron β\beta-decay data are analyzed. It is shown that the problem of Ellis-Jaffe and Bjorken sum rules deficiency and the neutron paradox could be solved simultaneously by assuming the small right handed current (RHC) admixture in the weak interaction Lagrangian. The possible RHC impact on pion-nucleon σ\sigma-term and Gamow-Teller sum rule for (p,n)(p,n) nuclear reactions is pointed out.Comment: to be published in Phys. Rev. Lett. LaTeX, 8 pages, 21 k

    Zero Mode and Symmetry Breaking on the Light Front

    Full text link
    We study the zero mode and the spontaneous symmetry breaking on the light front (LF). We use the discretized light-cone quantization (DLCQ) of Maskawa-Yamawaki to treat the zero mode in a clean separation from all other modes. It is then shown that the Nambu-Goldstone (NG) phase can be realized on the trivial LF vacuum only when an explicit symmetry-breaking mass of the NG boson mπm_{\pi} is introduced. The NG-boson zero mode integrated over the LF must exhibit singular behavior 1/mπ2 \sim 1/m_{\pi}^2 in the symmetric limit mπ0m_{\pi}\to 0, which implies that current conservation is violated at zero mode, or equivalently the LF charge is not conserved even in the symmetric limit. We demonstrate this peculiarity in a concrete model, the linear sigma model, where the role of zero-mode constraint is clarified. We further compare our result with the continuum theory. It is shown that in the continuum theory it is difficult to remove the zero mode which is not a single mode with measure zero but the accumulating point causing uncontrollable infrared singularity. A possible way out within the continuum theory is also suggested based on the ``ν\nu theory''. We finally discuss another problem of the zero mode in the continuum theory, i.e., no-go theorem of Nakanishi-Yamawaki on the non-existence of LF quantum field theory within the framework of Wightman axioms, which remains to be a challenge for DLCQ, ``ν\nu theory'' or any other framework of LF theory.Comment: 60 pages, the final section has been expanded. A few minor corrections; version to be published in Phys. Rev.

    New physics searches at near detectors of neutrino oscillation experiments

    Full text link
    We systematically investigate the prospects of testing new physics with tau sensitive near detectors at neutrino oscillation facilities. For neutrino beams from pion decay, from the decay of radiative ions, as well as from the decays of muons in a storage ring at a neutrino factory, we discuss which effective operators can lead to new physics effects. Furthermore, we discuss the present bounds on such operators set by other experimental data currently available. For operators with two leptons and two quarks we present the first complete analysis including all relevant operators simultaneously and performing a Markov Chain Monte Carlo fit to the data. We find that these effects can induce tau neutrino appearance probabilities as large as O(10^{-4}), which are within reach of forthcoming experiments. We highlight to which kind of new physics a tau sensitive near detector would be most sensitive.Comment: 20 pages, 2 figures, REVTeX

    Energy States of Colored Particle in a Chromomagnetic Field

    Get PDF
    The unitary transformation, which diagonalizes squared Dirac equation in a constant chromomagnetic field is found. Applying this transformation, we find the eigenfunctions of diagonalized Hamiltonian, that describe the states with definite value of energy and call them energy states. It is pointed out that, the energy states are determined by the color interaction term of the particle with the background chromofield and this term is responsible for the splitting of the energy spectrum. We construct supercharge operators for the diagonal Hamiltonian, that ensure the superpartner property of the energy states.Comment: 25 pages, some calculation details have been removed, typos correcte

    Weinberg like sum rules revisited

    Get PDF
    The generalized Weinberg sum rules containing the difference of isovector vector and axial-vector spectral functions saturated by both finite and infinite number of narrow resonances are considered. We summarize the status of these sum rules and analyze their overall agreement with phenomenological Lagrangians, low-energy relations, parity doubling, hadron string models, and experimental data.Comment: 31 pages, noticed misprints are corrected, references are added, and other minor corrections are mad

    Sum rules and dualities for generalized parton distributions: is there a holographic principle?

    Full text link
    To leading order approximation, the physical content of generalized parton distributions (GPDs) that is accessible in deep virtual electroproduction of photons or mesons is contained in their value on the cross-over trajectory. This trajectory separates the t-channel and s-channel dominated GPD regions. The underlying Lorentz covariance implies correspondence between these two regions through their relation to GPDs on the cross-over trajectory. This point of view leads to a family of GPD sum rules which are a quark analogue of finite energy sum rules and it guides us to a new phenomenological GPD concept. As an example, we discuss the constraints from the JLab/Hall A data on the dominant u-quark GPD H. The question arises whether GPDs are governed by some kind of holographic principle.Comment: 45 pages, 4 figures, Sect. 2 reorganized for clarity. Typos in Eq. (20) corrected. 4 new refs. Matches published versio

    An ecological future for weed science to sustain crop production and the environment. A review

    Get PDF
    Sustainable strategies for managing weeds are critical to meeting agriculture's potential to feed the world's population while conserving the ecosystems and biodiversity on which we depend. The dominant paradigm of weed management in developed countries is currently founded on the two principal tools of herbicides and tillage to remove weeds. However, evidence of negative environmental impacts from both tools is growing, and herbicide resistance is increasingly prevalent. These challenges emerge from a lack of attention to how weeds interact with and are regulated by the agroecosystem as a whole. Novel technological tools proposed for weed control, such as new herbicides, gene editing, and seed destructors, do not address these systemic challenges and thus are unlikely to provide truly sustainable solutions. Combining multiple tools and techniques in an Integrated Weed Management strategy is a step forward, but many integrated strategies still remain overly reliant on too few tools. In contrast, advances in weed ecology are revealing a wealth of options to manage weedsat the agroecosystem levelthat, rather than aiming to eradicate weeds, act to regulate populations to limit their negative impacts while conserving diversity. Here, we review the current state of knowledge in weed ecology and identify how this can be translated into practical weed management. The major points are the following: (1) the diversity and type of crops, management actions and limiting resources can be manipulated to limit weed competitiveness while promoting weed diversity; (2) in contrast to technological tools, ecological approaches to weed management tend to be synergistic with other agroecosystem functions; and (3) there are many existing practices compatible with this approach that could be integrated into current systems, alongside new options to explore. Overall, this review demonstrates that integrating systems-level ecological thinking into agronomic decision-making offers the best route to achieving sustainable weed management

    Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

    Get PDF
    BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)
    corecore